Bruce Wendel

Director at GT Biopharma.

Raised on GT Biopharma filings

$7.2M

of $27.2M offered across 3 Form D filings

Form D filings: 3
Teammates: 6
Last filing: May 28, 2025

Company

Biotech · San Francisco, CA

Immune cell engagers for leukemia and other blood cancers

Immune cell engagers for leukemia and other blood cancers

Investors: 6
Still open: $20M

Investors: 6
Sector: Biotech
HQ: San Francisco, CA

GT Biopharma filings

GT Biopharma Form D filings
Filed	Security	Sold of offered	Filing
May 28, 2025	Equity	None sold/ $20M	Form D
May 27, 2025	Equity	$6M/ $6M	Form D
Mar 7, 2025	Equity	$1.3M/ $1.3M	Form D

EquityFiled May 28, 2025Form D
None sold/ $20M
EquityFiled May 27, 2025Form D
$6M/ $6M
EquityFiled Mar 7, 2025Form D
$1.3M/ $1.3M

Works with

Also named on GT Biopharma filings

Alan UrbanChief Financial Officer, Form D signerForm D signer Charles CasamentoDirector Andrew RitterDirector Rajesh ShrotriyaDirector Hilary KramerDirector Michael BreenChief Executive Officer